Ascelia Pharma: Wrap up from interview Deputy CEO Julie W. Brogren

Ascelia Pharma yesterday participated at an event with HCA Capital following the release of its Q1 report last week. Although up more than 175 percent this year following the securing of non-diluting financing, successful completion of its pivotal SPARKLE study, and the recent release of very strong headline data from the study, Ascelia Pharma’s shares has actually been sliding more than 25 percent the last month. This probably reflect investors awaiting more details regarding the upcoming process of submitting an NDA (New Drug Application) for Orviglance to FDA and the plans for the commercialization process, so at yesterday’s event with HCA Capital, Deputy CEO and Chief Commercial Officer Julie Waras Brogren explained the company’s plans for the coming quarters on these matters sending up the shares almost 10 percent. Among other things Julie Waras Brogren confirmed ambitions that an Orphan Drug Designation and serving an unmet need will help Orviglance achieve a large share of the addressable market of approximately USD 400 millions annually in US. Ascelia Pharma could choose a standard or priority review from FDA, it is not unlikely that Orviglance will begin to be sold through partnerships already late 2025 or in the beginning of 2026.

To see the full event, use this link: Ascelia Pharma Q1 event

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. /Claus thestrup 08:50 AM 22-05-2024.